

## **Company Overview**

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

## NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference

Mar 1 2024, 7:05 AM EST

# **NeoGenomics Reports Fourth Quarter and Full Year 2023 Results**

Feb 20 2024, 4:05 PM EST

# **NeoGenomics Signs Working with Cancer Pledge in Support of Employees**

Feb 1 2024, 7:05 AM EST

#### **Stock Overview**

SymbolNEOExchangeNasdaqMarket Cap2.04bLast Price\$15.9652-Week Range\$11.03 - \$21.22

### 03/07/2024 04:00 PM EST

## **Executive Team**

#### **Chris Smith**

Chief Executive Officer

#### **Jeffrey Sherman**

Chief Financial Officer

# **Melody Harris**

**President Enterprise Operations** 

## **Warren Stone**

President Clinical Division

#### Vishal Sikri

President Pharma Services, President and Chief Commercial Officer Inivata

## **Gary Passman**

Chief Culture Officer

#### Hutan Hashemi

Chief Compliance Officer

### Ali Olivo

General Counsel and Corporate Secretary

## NeoGenomics, Inc.

9490 NeoGenomics Way Fort Myers, FL 33912

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.